BD completes acquisition of Critical Care from Edwards Lifesciences

BD announced that it has completed the acquisition of Edwards Lifesciences' Critical Care product group, which will be renamed as BD Advanced Patient Monitoring.

BD Advanced Patient Monitoring provides advanced monitoring solutions and will expand BD's portfolio of smart connected care solutions with its growing set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline. BD Advanced Patient Monitoring's technologies are often used simultaneously with the BD Alaris Infusion System in the operating room or intensive care units. The combination of BD's new advanced monitoring and existing infusion platforms enables future innovation opportunities for closed-loop hemodynamic monitoring and IV fluid and medication administration by integrating combined company data sets and interoperability capabilities.

BD Advanced Patient Monitoring's portfolio includes the Swan Ganz pulmonary artery catheter, minimally invasive sensors, noninvasive cuffs, tissue oximetry sensors and monitors. Its smart technologies are driven by advanced data analytics with machine learning and AI-based predictive and prescriptive algorithms to help clinicians better understand current and future patient conditions and provide clinical decision support tools.

BD Advanced Patient Monitoring will operate as a separate business unit within BD's Medical segment